share_log

Equillium Analyst Ratings

Equillium Analyst Ratings

Equillium 分析師評級
Benzinga ·  2023/08/14 18:23
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/14/2023 575.01% HC Wainwright & Co. → $5.5 Reiterates Buy → Buy
05/15/2023 575.01% HC Wainwright & Co. → $5.5 Reiterates Buy → Buy
05/01/2023 575.01% HC Wainwright & Co. $20 → $5.5 Maintains Buy
03/24/2023 759.11% Stifel $12 → $7 Maintains Buy
02/08/2023 759.11% SVB Leerink $12 → $7 Maintains Outperform
09/27/2022 2354.59% HC Wainwright & Co. $15 → $20 Maintains Buy
09/08/2022 1372.75% SVB Leerink $14 → $12 Maintains Outperform
03/24/2022 1740.94% HC Wainwright & Co. $12 → $15 Maintains Buy
01/05/2022 1618.21% SVB Leerink $18 → $14 Maintains Outperform
09/15/2021 1618.21% Cantor Fitzgerald → $14 Initiates Coverage On → Overweight
03/03/2021 1618.21% JonesTrading → $14 Initiates Coverage On → Buy
11/30/2020 1372.75% HC Wainwright & Co. $22 → $12 Maintains Buy
08/21/2020 2600.05% HC Wainwright & Co. $24 → $22 Maintains Buy
07/14/2020 2845.51% HC Wainwright & Co. $14 → $24 Reiterates → Buy
07/02/2019 1618.21% HC Wainwright & Co. → $14 Initiates Coverage On → Buy
11/06/2018 2600.05% Stifel → $22 Initiates Coverage On → Buy
11/06/2018 2231.86% Jefferies → $19 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年08月14日 575.01% HC Wainwright公司 →$5.5 重申 購買→購買
2023年05月15日 575.01% HC Wainwright公司 →$5.5 重申 購買→購買
05/01/2023 575.01% HC Wainwright公司 $20→$5.5 維護
03/24/2023 759.11% Stifel $12→$7 維護
02/08/2023 759.11% SVB Leerink $12→$7 維護 跑贏大盤
09/27/2022 2354.59% HC Wainwright公司 $15→$20 維護
09/08/2022 1372.75% SVB Leerink $14→$12 維護 跑贏大盤
03/24/2022 1740.94% HC Wainwright公司 $12→$15 維護
01/05/2022 1618.21% SVB Leerink $18→$14 維護 跑贏大盤
2021/09/15 1618.21% 康託·菲茨傑拉德 →$14 開始承保 →超重
03/03/2021 1618.21% Jones Trading →$14 開始承保 →購買
11/30/2020 1372.75% HC Wainwright公司 $22→$12 維護
2020年08月21日 2600.05% HC Wainwright公司 $24→$22 維護
07/14/2020 2845.51% HC Wainwright公司 $14→$24 重申 →購買
2019年07月02日 1618.21% HC Wainwright公司 →$14 開始承保 →購買
2018/06/11 2600.05% Stifel →$22 開始承保 →購買
2018/06/11 2231.86% 傑富瑞 →$19 開始承保 →購買

What is the target price for Equillium (EQ)?

Equillium(EQ)的目標價是多少?

The latest price target for Equillium (NASDAQ: EQ) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $5.50 expecting EQ to rise to within 12 months (a possible 575.01% upside). 7 analyst firms have reported ratings in the last year.

HC Wainwright&Co.於2023年8月14日報道了Equillium(納斯達克:EQ)的最新目標價。這家分析公司將目標價定為5.5美元,預計EQ將在12個月內升至(可能上漲575.01%)。去年有7家分析公司公佈了評級。

What is the most recent analyst rating for Equillium (EQ)?

分析師對Equillium(EQ)的最新評級是多少?

The latest analyst rating for Equillium (NASDAQ: EQ) was provided by HC Wainwright & Co., and Equillium reiterated their buy rating.

分析師對Equillium(納斯達克代碼:EQ)的最新評級由HC Wainwright&Co.提供,Equillium重申其買入評級。

When is the next analyst rating going to be posted or updated for Equillium (EQ)?

Equillium(EQ)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Equillium, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Equillium was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.

分析師在進行了廣泛的研究後得出股票評級,其中包括查閱公開財務報表,與Equillium的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Equillium的上一次評級是在2023年8月14日提交的,所以你應該預計下一次評級將在2024年8月14日左右的某個時候公佈。

Is the Analyst Rating Equillium (EQ) correct?

分析師評級Equillium(EQ)正確嗎?

While ratings are subjective and will change, the latest Equillium (EQ) rating was a reiterated with a price target of $0.00 to $5.50. The current price Equillium (EQ) is trading at is $0.81, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Equillium(EQ)評級被重申,目標價在0.00美元至5.50美元之間。Equillium目前的交易價格為0.81美元,在分析師的預測範圍內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論